Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Construction in Progress Convertible Debt Current Assets Current Deferred Revenue Current Leases Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Deferred Tax Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Non-Current Deffered Revenue Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Daily Values

Growth Metrics

Others

Pelthos Therapeutics (PTHS) Cash & Equivalents (2024 - 2025)

Pelthos Therapeutics has reported Cash & Equivalents over the past 2 years, most recently at $18.0 million for Q4 2025.

Quarterly results put Cash & Equivalents at $18.0 million for Q4 2025, up 3403.51% from a year ago — trailing twelve months through Dec 2025 was $18.0 million (up 3403.51% YoY), and the annual figure for FY2025 was $18.0 million, up 3403.51%.
Cash & Equivalents for Q4 2025 was $18.0 million at Pelthos Therapeutics, up from $14.2 million in the prior quarter.
Over the last five years, Cash & Equivalents for PTHS hit a ceiling of $18.0 million in Q4 2025 and a floor of $59172.0 in Q2 2025.